Sage Journals: Discover world-class research

Abstract

The amyloid-beta peptide (Aβ) induces apoptosis in cerebrovascular endothelial cells (CECs), contributing to the pathogenesis of cerebral amyloid angiopathy. We have previously shown that Aβ induces apoptosis in CECs. In the present study, we report that Aβ_25–35-induced CEC apoptosis involves the inactivation of Akt, a signaling kinase important in maintaining cell viability. Akt prevents the activation of death-signaling events by facilitating the inactivation of proapoptotic proteins such as Bad. We applied three strategies to show that Aβ_25–35 inactivation of Akt is causally related to Aβ_25–35-induced CEC death by preventing Bad activation and subsequent mitochondrial dysfunction (reflected by the release of endonuclease G and Smac, two proapoptotic intermembranous proteins of the mitochondria). Wortmannin, a PI₃-kinase inhibitor, enhanced Aβ_25–35-induced Bad activation, mitochondrial dysfunction and CEC death. Enhancement of Akt activity by a Tat—Akt fusion protein, or by viral gene transfer of a constitutively active mutant of akt, reduced Bad activation, mitochondrial dysfunction, and CEC death. Using a siRNA strategy to knock down the bad gene, we showed that Bad activation is causally related to Aβ_25–35-induced mitochondrial dysfunction and CEC death. Together, these results establish that the Akt—Bad cascade is altered by Aβ_25–35, resulting in CEC apoptosis.

Keywords

amyloid angiopathy apoptosis endonuclease G Smac Tat—Akt

Introduction

Alzheimer's disease (AD) is a neurodegenerative disease that results from the progressive deposition of fibrillar amyloid-β peptide (Aβ) in senile plaques in the brain (Wisniewski and Wegiel, 1995; Yankner, 1996). While considerable attention has focused on parenchymal Aβ accumulation and neuronal degeneration in AD brains (Yankner et al, 1989; Behl et al, 1994), Aβ also accumulates in the cerebrovascular walls of AD patients and in nondemented elderly individuals, leading to cerebral amyloid angiopathy (Perlmutter et al, 1994; Wisniewski et al, 2000). One of the most widely recognized complications of amyloid angiopathy is hemorrhagic strokes (Walker, 1997). Amyloid-β peptide is toxic to cerebral endothelial cells (CECs) (Price et al, 1997; Preston et al, 1998; Xu et al, 2001; Yin et al, 2002b), and may contribute to alterations in cerebral blood flow (Iadecola et al, 1999). Amyloid-β peptide causes CEC death with morphological and molecular features suggestive of apoptosis (Blanc et al, 1997; Hase et al, 1997; Suo et al, 1997; Xu et al, 2001; Yin et al, 2002b). In particular, mitochondrial dysfunction has been prominently shown in CECs exposed to Aβ (Xu et al, 2001; Yin et al, 2002b). However, the molecular mechanism underlying Aβ-induced mitochondrial dysfunction and apoptosis in CECs remains to be fully characterized.

Akt (a.k.a. protein kinase B), a serine/threonine kinase with oncogenic properties (Burgering and Coffer, 1995; Franke et al, 1995), serves as an antiapoptotic regulator, controlling the balance between survival and apoptosis in growth factor-mediated cytoprotection (Burgering and Coffer, 1995; Ahmed et al, 1997; Dudek et al, 1997). Akt is activated in a PI₃-kinase-dependent manner by phosphorylation at two regulatory sites: threonine 308 (Thr 308) and serine 473 (Ser 473) (Franke et al, 1995, 1997; Klippel et al, 1997; Sable et al, 1998). Fully activated Akt, in turn, functions to promote cell survival by selectively phosphorylating and inactivating several downstream proapoptotic targets including the BH3-only protein, Bad (Datta et al, 1997; del Peso et al, 1997). While a role for Akt has been established in growth factor-mediated survival, little is known regarding its potential role under conditions of pathological neurodegeneration, such as that seen in cerebral amyloid angiopathy.

Mitochondrial dysfunction has been implicated as a key event in apoptosis in a number of cell death paradigms (Green and Reed, 1998). Several cellular processes characterize mitochondrial dysfunction and activation of apoptosis in Aβ-induced CEC death. These include mitochondrial release of cytochrome c (Xu et al, 2001), Smac (Yin et al, 2002b), and endonuclease G (Endo G) (as shown in the present study). Cytochrome c triggers caspase activation through interaction with Apaf-1 (Liu et al, 1996; Li et al, 2000). Second mitochondria-derived activator of caspase (Smac, a.k.a. DIABLO) relieves Inhibitor of Apoptosis Proteins (IAPs) from inhibiting caspases (Du et al, 2000; Verhagen et al, 2000). However, mitochondrial release of Endo G causes nuclear chromatin condensation and fragmentation in a caspase-independent manner (Li et al, 2001; Cregan et al, 2002). The preferential release of select proapoptotic proteins from mitochondria might be subject to differential upstream regulation (Kandasamy et al, 2003). The Akt cascade, via its control of Bad activity, has emerged as an important regulatory mechanism upstream of mitochondria in the maintenance of cell viability. In the present study, we explore the roles of Akt and Bad and related cellular events in Aβ-induced mitochondrial dysfunction and cell death in CECs.

Materials and methods

Murine Cerebrovascular Endothelial Cell Primary Cultures

Murine CECs were prepared as described previously (Xu et al, 1992). Murine CECs migrating from the vessels were pooled to form a proliferating cell culture that was maintained in DMEM, with high glucose and l-glutamine supplemented with 10% FBS, 0.5mg/ml heparin, and 75μg/ml endothelial cell growth supplements. Murine CECs of passage 4–15 that were uniformly positive for factor VIII and vimentin (495% endothelial cell purity) and characteristic bradykinin receptors were grown to 85% to 95% confluency before use (Xu et al, 1992).

Treatment with Aβ and Other Chemicals

Aβ_1–40 and Aβ_1–42 are the major components of Aβ deposits in the AD brain; however, in most experimental systems, the biological effects of Aβ_25–35 are comparable (Loo et al, 1993; Behl et al, 1994). We have previously shown that Aβ_25–35 has approximately the same potency as Aβ_1–40 in inducing cell death in CECs (Xu et al, 2001; Yin et al, 2002b). Based on these data, we employed Aβ_25–35 in this study. Cerebrovascular endothelial cells were treated with 25μmol/L Aβ_25–35 (Sigma, St Louis, MO, USA) in serum-free growth medium for varying times. In some experiments, the murine CECs were co-treated with wortmannin at concentrations of 0.1, 1, and 10μmol/L.

Western Blot Analysis

Subfractionization of cellular components in CECs was performed as previously reported, with little cross-contamination of fractionated proteins (Xu et al, 2001; Yin et al, 2002b). Protein samples (20 to 40μg) were electrophoresed on a 10% to 15% SDS-PAGE gel, transferred to PVDF membranes and probed with primary antibodies including rabbit anti-Endo G antibody (1:2,500, a generous gift from Dr XD Wang), goat anti-smac antibody, rabbit anti-Akt antibody, rabbit anti-phospho-Akt (Thr 308) antibody, rabbit anti-phospho-Akt (Ser 473) antibody, rabbit anti-Bad antibody, rabbit anti-phospho-Bad (Ser 136) antibody (1:1,000; Cell Signaling, Beverly, MA, USA), and mouse anti-actin antiserum (1:200; Santa Cruz, CA, USA) for 1–2 h at room temperature. The membranes were then incubated with the second antibody (1:5,000; anti-rabbit, anti-mouse or anti-goat IgG conjugated with alkaline phosphatase Promega, Madison, WI, USA) at room temperature for 1 h. The color reaction was developed using the Blot AP System (Promega, Madison, WI, USA) according to the manufacturer's instructions.

Immunofluorescent Staining

Murine CECs grown on coverslips were fixed with 4% paraformaldehyde for 30mins and washed 3 times with 0.1 mol/L PBS (pH 7.4). The cells were then incubated with a primary rabbit anti-Endo G antibody (1:500, overnight at 4°C). The next day, the cells were incubated with fluorescein-conjugated anti-rabbit IgG (1:100; Vector Labs, Burlingame, CA, USA) for 1 h. Cerebrovascular endothelial cells were counterstained with 1μg/mL of PI (Molecular Probes, Eugene, OR, USA) to visualize nuclear morphology. Slides were washed, wet mounted, and examined with an Olympus fluorescence microscope.

Generation and Purification of Tat—Akt Fusion Protein

The Tat—Akt fusion protein was prepared as described previously (Schwarze et al, 1999).

Construct design: Two mutant mouse akt plasmid cDNAs were kindly provided by Dr Tsichlis: pCMV-HA-K179m-AKT, a kinase-inactive mutant (Akt_m), and pCMV-HA-myr-AKT, a constitutively active myristolated mutant (Akt_ca) (Franke et al, 1995). The coding region of each plasmid was amplified by PCR with the following primers: 5'-ATGAACGACGTAGCCATTG-3', and 5'-TCAGGCTGTG CCACTG-3', adding KpnI and EcoRI restriction sites at the N and C termini, respectively. Amplimer identity was confirmed by restriction digestion, then cloned into pTAT-HA using the same restriction sites. The DNA sequence was verified by sequencing analysis.

Protein production and isolation: Recombinant plasmids were transformed into Escherichia coli BL21 cells and protein expression was induced using 0.1 mmol/L isopropylthiogalactoside at 37°C for 5 to 6 h. The fusion proteins were purified using a Ni-NTA superflow agarose column (Qiagen, Valencia, CA, USA), followed by a PD-10 column, pre-equilibrated with serum-free culture medium containing 10% glycerol, and then stored in 10% glycerol/PBS at −80°C until use.

Detection of protein transduction: Cerebrovascular endothelial cells were seeded on coverslips before the Tat—Akt fusion protein was added at a final concentration of 100nmol/L, incubated for 10 to 30mins at 37°C, and washed in PBS. Cells fixed in 4% paraformaldehyde were incubated with mouse anti-HA monoclonal antibody (1:200, Santa Cruz, CA, USA), then with fluorescein-conjugated anti-mouse IgG (1:100; Vector Labs, Burlingame, CA, USA). The coverslips were washed, wet mounted, and examined with an Olympus fluorescence microscope.

Construction of Retrovirus-Mediated Overexpression of Akt in Cerebrovascular Endothelial Cells

The mutant akt cDNAs (pCMV-HA-K179m-AKT, pCMV-HA-myr-AKT) (Franke et al, 1995) were also amplified by PCR to construct viral vectors for gene transfer. The primers used were as follows: 5'-ACAGCTAGCATGAACG ACGTAGCCATTGTG-3' (antisense primer), 5'-ATATCTAG ATCAGGCTGTGCCACTGGCTG-3' (sense primer). The PCR products were cloned into a pGEM-T Easy vector (Promega, Madison, WI, USA) and isolated by digestion with NheI–XbaI restriction enzymes and subcloned into the NheI–XbaI sites of pMX-internal ribosomal entry site (IRES)-EGFP (Kitamura et al, 1995). The resulting plasmid contained the akt gene, an IRES, and an EGFP gene. For production of high-titer retroviruses expressing Akt, Phoenix ecotropic packaging cells were plated at approximately 50% to 75% confluency in 15-cm-diameter tissue culture plates and pMX-AKT-IRES-EGFP vector DNAs were transfected into Phoenix retroviral producer cells by the modified calcium phosphate method. After incubation for 2 days at 32°C, viral supernatant was collected and passed through a 0.45μm filter. Cerebrovascular endothelial cells were infected with retroviral supernatant in the presence of Polybrene at 5μg/mL and incubated for 3 h. Retroviral supernatant was removed and replaced with normal growth medium. Cells grown for 48 to 72 h were sorted by flow cytometry. Infected populations exhibiting between 60% and 75% green fluorescent cells were used for further experimentation.

RT-PCR

Bad mRNA expression was detected by RT-PCR (Yin et al, 2002a). Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA, USA). In all, 600 ng of RNA was used for the synthesis of cDNA and PCR reactions. Primers were designed based on the mouse bad sequences (forward: 5'-GGAAGACGCTAGTGCTACAG-3', reverse: 5'-GAGCCTCCTTTGCCCAAGTT-3'). The relative bad mRNA level of was normalized to endogenous cyclophilin mRNA for each sample.

Co-immunoprecipitation

Co-immunoprecipitation was prepared as described previously (Xu et al, 2001; Yin et al, 2002b). Aβ_25–35-treated CECs were homogenized in lysis buffer and the supernatant was incubated with rabbit anti-Bcl-xL antibody. Protein G sepharose 4 fast flow (Pharmacia Biotech, Piscataway, NJ, USA) was added to the antigen—antibody mixture and incubated with gentle agitation for 1 to 2 h. The immunoprecipitate was washed with lysis buffer, resuspended in 6 × SDS loading buffer, separated in SDS-PAGE gel, transferred to PVDF membrane, and then analyzed by Western blotting with rabbit anti-Bad antibody (1:1,000) as described above.

Bad Knockdown in Cerebrovascular Endothelial Cells with RNA Interference

SiRNAs targeting the mouse bad gene were prepared by in vitro transcription using Silencer™ siRNA Construction Kit (Ambion, Austin, TX, USA). SiRNA was synthesized to target the coding region of mouse bad mRNA as follows: 5'-UUCUGCGAUCACGAUGUCUAU-3', and scrambled: 5'-UUGUCUCAUGUCGUCUAGACA-3'. Murine CECs were transfected 24 h after plating, using 2 to 4μL siPORT Lipid (Ambion, Austin, TX, USA) according to the manufacturer's protocol, at a final siRNA concentration of 100nmol/L. Bad mRNA and Bad protein levels were examined by RT-PCR and Western blotting 48 to 72 h after transfection.

Assessment of Murine Cerebrovascular Endothelial Cell Death

3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) assay: Cerebrovascular endothelial cells were rinsed with HBSS and replaced with DMEM containing MTT (Sigma, St Louis, MO, USA) at a final concentration of 0.5mg/mL. The cells were then incubated for 4 h at 37°C under 5% CO₂/95% air, and for another 14 h in lysis solution (10% SDS in 0.01 N HCl) at 1:1 dilution. Absorbance of the mixture was read at 540 nm using a multiplate reader. Viability was expressed as OD₅₄₀ of treated cells divided by OD₅₄₀ of untreated cells (Yin et al, 2002a, b).

l-lactate dehydrogenase release: In all, 25μL of medium was taken from each sample and placed into a 96-well plate; 125μL LDH buffer (0.1 mol/L, pH 7.4, 1:2 of KH₂PO₄ and K₂HPO₄) and 100μL NADH solution (0.03% NADH in LDH buffer) were added to each sample well. After incubation for 5mins, 25μL pyruvate solution (22.7mmol/L pyruvate in LDH buffer) was added and absorbance was determined at 340nm. LDH release was expressed as U/mL after normalization to l-lactate dehydrogenase (LDH) standards (1000 U/mL, Sigma) (Yin et al, 2002a, b).

Statistical analysis: Quantitative data are expressed as mean × s.d., based on at least three separate experiments of triplicate samples. Difference among groups was statistically analyzed by one-way analysis of variance followed by Bonferroni's post hoc t-test. Comparison between two experimental groups was based on two-tailed t-test. A P-value less than 0.05 was considered significant.

Results

Aβ25–35 Inactivation of Akt in Cerebrovascular Endothelial Cells

Akt plays a central role in cell survival by preventing the activation of a variety of proapoptotic pathways. Akt is activated in a PI₃-kinase-dependent manner by phosphorylation at two regulatory sites: Thr 308 and Ser 473 (Franke et al, 1995, 1997; Klippel et al, 1997; Sable et al, 1998). To determine whether Akt inactivation is involved in Aβ_25–35-induced CEC death, we first measured levels of total and phosphorylated Akt (at Thr 308 and Ser 473) by Western blot analysis. Exposure to Aβ_25–35 (25μmol/L) resulted in a substantial decrease in the active forms of Akt at both Thr 308 and Ser 473, as early as 1 h after treatment; but had no effect on total Akt levels until 24 h (Figures 1A and 1B). No significant changes in Akt activation were observed in control cultures between 0 and 24 h (data not shown).

Figure 1

Aβ_25–35 inactivation of Akt in CECs. (A) Cerebrovascular endothelial cells treated with 25μmol/L Aβ_25–35 for the indicated times were analyzed by Western blotting using anti-Akt, anti-p-Akt (at Thr 308 and Ser 473), and anti-actin antibodies. Akt inactivation reflected by a decrease in Akt phosphorylation is evident within 1 h, while little change in the total Akt level was observed until 24 h after Aβ_25–35 exposure. (B) Quantitative analysis of three Western blots (normalized to actin) using the NIH Image Analysis System graphically illustrates decreased Akt phosphorylation by Aβ_25–35. Data shown in panel A are representative of three separate experiments with similar results. Data in panel B are expressed as mean×s.d. *P < 0.05 versus 0 h exposure.

Aβ25–35 Dephosphorylation of Bad in Cerebrovascular Endothelial Cells

Fully activated Akt promotes cell survival by selectively phosphorylating and inactivating several downstream proapoptotic targets including the BH3-only protein, Bad (Datta et al, 1997; del Peso et al, 1997). Under normal physiological conditions, Bad, in the phosphorylated and inactive form, is known to exist almost exclusively in the cytoplasm (Cross et al, 1995; Datta et al, 1997; del Peso et al, 1997; Hajduch et al, 1998; Brunet et al, 1999; Kaplan and Miller, 2000). Reduced Akt activity would be expected to favor the dephosphorylation of Bad (rendering the protein active). Activated Bad, recognized as an essential initiator of the apoptotic cascade (Kelekar and Thompson, 1998; Huang and Strasser, 2000), translocates to mitochondria where it binds Bcl-x_L, an antiapoptotic member in the Bcl-2 family, resulting in mitochondrial membrane disruption, mitochondrial dysfunction, and subsequent cell death (Yang et al, 1995; Zha et al, 1996; Korsmeyer, 1999). In view of the inactivation of Akt by Aβ_25–35, we examined if Bad was activated after exposure to Aβ_25–35. Aβ_25–35 decreased phospho-Bad (Ser 136) levels in the cytosolic fraction as early as 4 h after exposure, in parallel with an increase in the Bad content in the mitochondrial fraction (Figure 2A), indicating that dephosphorylated Bad translocated from the cytoplasm to mitochondria. We have previously reported that Aβ_25–35 induced CEC death beginning 24 h after treatment (Xu et al, 2001), suggesting that Bad translocation preceded cell death. In addition, Bcl-x_L co-immunoprecipitated with Bad in Aβ-treated CECs, suggesting a physical interaction between these two Bcl-2 family members during the apoptotic process (Figure 2B). Aβ_25–35 had little effect on bad mRNA levels, suggesting that Bad activation involved primarily post-transcriptional regulation (Figure 2C). No significant change in Bad phosphorylation was observed in control cultures between 0 and 48 h (data not shown).

Figure 2

Aβ_25–35 activation of Bad. Cerebrovascular endothelial cells treated with 25μmol/L Aβ_25–35 at the indicated times were fractionated and examined by Western blotting with anti-Bad or anti-p-Bad (Ser 136) antibodies. Cytosolic and inactive (or phosphorylated) Bad (Cyto.p-Bad) decreased 4 h after Aβ treatment, in parallel with the appearance of Bad in the mitochondrial fraction (A). Immunoprecipitation with anti-Bcl-x_L antibodies followed by immunoblotting with anti-Bad antibodies revealed that Bad co-immunoprecipitated with Bcl-x_L 8–24 h after Aβ_25–35 treatment (B). Analysis with RT-PCR revealed that bad mRNA levels remained unchanged after Aβ_25–35 exposure in CECs (C). Data shown are representative of three separate experiments with similar results.

Endonuclease G Translocation from Mitochondria to Nucleus After Aβ25–35 Exposure

Previous studies have shown that the release of mitochondrial intermembranous proteins after apoptotic stimuli might be under the control of some BH3-only family members, including Bad (Li et al, 2001; Wang, 2001; Madesh et al, 2002). These mitochondrial intermembranous proteins include cytochrome c, Smac and Endo G. Aβ_25–35-induced Bad activation and translocation to mitochondria in CECs, as shown above, would be expected to cause mitochondrial dysfunction. We have previously shown that Aβ_25–35 induced cytochrome c and Smac release, leading to CEC apoptosis (Xu et al, 2001; Yin et al, 2002b). In the present study, we found that Aβ_25–35 treatment caused an increase in Endo G in the nuclear fraction and a decrease in the mitochondrial fraction, indicating translocation from mitochondria to nucleus (Figure 3A). This subcellular redistribution was confirmed by immunofluorescent staining with an anti-Endo G antibody. The punctate mitochondrial staining pattern observed in control cultures changed to a dense nuclear pattern after Aβ_25-35 treatment (Figure 3B).

Figure 3

Aβ_25–35-induced translocation of Endo G from mitochondria to nucleus. Cerebrovascular endothelial cells, treated with 25μmol/L Aβ_25–35 and harvested at times indicated, were fractionated into mitochondrial (Mito.) and nuclear (Nuc.) extracts, separated by SDS-PAGE, and analyzed by Western blotting with anti-Endo G, anti-Actin, or anti-Cox IV antibodies (A). Actin and Cox IV bands reflect equal protein loading for the nuclear and mitochondrial fractions, respectively. Cerebrovascular endothelial cells, grown on coverslips and treated with 25μmol/L Aβ_25–35 for 24 h, were fixed and immunostained with anti-Endo G antibody (green); nuclei were counterstained with PI (red) (B). Note the change in Endo G immunostaining from a punctate mitochondrial to a nuclear pattern in some CECs showing condensed nuclei (yellow) after treatment with Aβ_25–35. Magnification: × 1000. Data shown are representative of three separate experiments with similar results.

Akt Regulation of Aβ25–35-Induced Mitochondrial Dysfunction and Cell Death

Release of mitochondrial intermembranous proteins might be regulated by multiple upstream signaling pathways (Imaizumi et al, 1999; Kaltschmidt et al, 1999; Bozyczko-Coyne et al, 2001; Martin et al, 2001). If Bad-initiated mitochondrial dysfunction (including mitochondrial release of Smac and Endo G) and CEC death is under the regulation of Akt, alteration of Akt activity would be expected to affect cellular events downstream of Bad as well. We applied three strategies to determine if Akt was involved in Aβ_25-35-induced Bad activation and subsequent release of mitochondrial intermembranous proteins. The first was to determine whether inhibition of Akt affects Aβ_25–35-induced mitochondrial dysfunction and cell death. Wortmannin, a PI₃/ Akt inhibitor at doses between 30nmol/L and 1μmol/L (Dimmeler et al, 1998; Fujio and Walsh, 1999; Kim et al, 2000), enhanced Aβ_25–35-induced Bad translocation from the cytoplasm to mitochondria in a dose-dependent manner (Figure 4A). This effect was accompanied by enhanced Endo G translocation to the nucleus, and Smac release into cytosol, in a dose-dependent manner (Figure 4A). Wortmannin also increased Aβ_25–35-induced cell death (Figure 4B).

Figure 4

Effects of Akt inhibition on Bad translocation, mitochondrial intermembranous protein release, and CEC death induced by Aβ_25–35. (A) Cerebrovascular endothelial cells, treated with 25μmol/L Aβ_25–35 in the presence or absence of the Akt inhibitor, wortmannin, were fractionated and analyzed by Western blotting with antibodies indicated. Wortmannin significantly increased Aβ_25–35-induced Bad translocation to mitochondria (Mito. Bad) after Aβ_25–35 exposure for 4 h, Endo G translocation to nucleus (Nuc.Endo G) and Smac release into cytoplasm (Cyto.Smac) after Aβ_25–35 exposure for 24 h in a dose-dependent manner. Western blots are representative of three separate experiments with similar results. (B) Wortmannin increased CEC death (determined by MTT assay and LDH assay) after Aβ_25–35 exposure for 24 h. Data shown are expressed as mean×s.d. from three separate experiments in quadruplicate. **P < 0.05 versus the control groups (CECs treated with Aβ_25–35 only).

The second strategy entailed enhancement of Akt activity with cellular transfer of a constitutively active myristylated mutant Tat—Akt (Tat—Akt_ca) fusion protein, using a kinase-inactive mutant Tat—Akt (Tat—Akt_m) as a negative control. Successful delivery of both fusion proteins (500nmol/L) into CECs was confirmed by Western blotting (Figure 5A). In addition, effective transduction of the Tat—Akt_ca and Tat—Akt_m protein was further confirmed by immunostaining with anti-HA antibody in CECs (Figure 5B). As expected, Tat—Akt_ca, but not Tat—Akt_m, increased phospho-Akt (Thr 308 and Ser 473) (Figure 5A). Treatment with Tat—Akt_ca, but not Tat—Akt_m, effectively inhibited Aβ_25–35-induced Bad translocation to mitochondria and subsequent mitochondrial release of Smac and Endo G to cytosol and nucleus, respectively (Figure 5C). Tat—Akt_ca protected CECs from Aβ_25–35-induced cell death (Figure 5D), while Tat—Aktm had no effect on Aβ_25–35-induced mitochondrial protein release, and subsequent cell death (Figures 5C and 5D).

Figure 5

Effects of Tat—Akt fusion protein delivery on Aβ₂₅-35-induced Bad translocation, Endo G and Smac release, and CEC death. (A) Cerebrovascular endothelial cells, treated with 25μmol/L Aβ_25-35 in the presence or absence of 500nmol/L constitutively active myristylated mutant Tat—Akt fusion protein (Tat—Akt_ca) or a kinase-inactive mutant Tat—Akt fusion protein (Tat—Akt_m), were fractionated and examined by Western blotting. An increase in cytosolic p-Akt (Thr 308 and Ser 473) was only observed with Tat—Akt_ca treatment. (B) Tat—Akt_ca or Tat—Akt_m fusion protein delivery was confirmed by immunostaining using an anti-HA monoclonal antibody. Magnification: × 200. (C) Western blotting showed that Tat—Akt_ca, but not Tat—Akt_m, delivery significantly reduced Aβ_25–35-induced Bad translocation and subsequent mitochondrial Endo G and Smac release (Mito.Bad, mitochondrial Bad; Nuc.Endo G, nuclear Endo G; Cyto.Smac, cytosolic Smac). (D) Tat—Akt_ca, but not Tat—Akt_m, treatment decreased CEC death after Aβ_25–35 exposure for 24 h. Data shown in panels A, B, and C are representative of three separate experiments with similar results. Data shown in panel D are expressed as mean ± s.d. from three separate experiments in quadruplicate. **P < 0.05 versus the control groups (CECs treated with Aβ_25–35 or Aβ_25–35 plus Tat—Akt_m delivery).

The third strategy involved the upregulation of Akt activity in Aβ_25–35-treated CECs using retroviral gene transfer of akt_ca (pMX/Akt_ca), or akt_m (pMX/Akt_m), which served as a negative control. Infection with both akt-carrying viruses increased total Akt protein levels, while only pMX/Akt_ca increased phospho-Akt levels in CECs (Figure 6A). Effective gene transfer was also confirmed by immunofluorescence, which revealed abundant cytoplasmic staining of the virally expressed reporter, GFP (Figure 6B). Akt_ca gene transfer attenuated Aβ_25–35-induced Bad translocation to the mitochondria and the subsequent release of Endo G (Figure 6C) and Smac (data not shown), and cell death (Figure 6D), while gene transfer of the kinase inactive mutant akt_m had none of these effects. Results of these experiments further implicate the causal role of Akt in regulating Aβ_25–35-induced Bad activation and mitochondrial dysfunction, leading to CEC apoptosis.

Figure 6

Effects of Akt upregulation by retroviral akt gene transfer on Aβ_25-35-induced Bad translocation, Endo G and CEC death. (A) Western blotting shows total Akt and phospho-Akt levels after infection with retroviral vectors carrying kinase-inactive mutant akt (pMX/Akt_m) or constitutively active myristylated akt (pMX/Akt_ca). (B) Effective gene transfer to CECs was confirmed by GFP fluorescence. Magnification: × 200. (C) Constitutively active akt, but not kinase-inactive akt, gene transfer significantly reduced Bad translocation and subsequent mitochondrial Endo G release after Aβ_25–35 treatment for 24 h (Mito.Bad, mitochondrial Bad; Nuc.Endo G, nuclear Endo G). (D) Transfer of the constitutively active akt, but not kinase inactive akt, gene decreased Aβ_25–35-induced CEC death. Data shown in panels A, B, and C are representative of three separate experiments with similar results. Data shown in panel D are expressed as mean × s.d. from three separate experiments in quadruplicate. **P < 0.05 versus the control groups (CECs treated with Aβ_25–35 or Aβ_25–35 plus pMX/Akt_m gene transfer).

Effects of bad Knockdown with siRNA on Mitochondrial Dysfunction and Cell Death

Since mitochondrial release of intermembranous proteins such as Smac and Endo G is under the control of BH3-only family members including Bad (Li et al, 2001; Wang, 2001; Madesh et al, 2002), we examined if Bad activation was causally related to Aβ_25–35-induced mitochondrial dysfunction and CEC death. Cerebrovascular endothelial cells were treated with siRNA specific for bad without Aβ_25–35 exposure. Bad mRNA levels were significantly repressed by treatment with 100nmol/L bad siRNA (Figure 7A). SiRNA treatment also decreased Aβ_25–35-induced Bad translocation to mitochondria (Mito Bad, Figure 7B), and reduced Endo G translocation from mitochondria to nucleus (Nuc Endo G, Figure 7B). Smac translocation from mitochondria to cytoplasm was also decreased (Cyto Smac, Figure 7B). Finally, bad knockdown with siRNA also attenuated Aβ_25–35-induced CEC death (Figure 7C). The specificity of this bad siRNA strategy was supported by the finding that scrambled bad siRNA was without effect on Aβ_25–35-induced Bad activation, mitochondrial release of Smac and Endo G, and the extent of CEC death. Furthermore, bad siRNA did not alter cyclophilin mRNA levels.

Figure 7

Effects of bad1 knockdown on Endo G and Smac translocation and CEC death. (A) Total RNA from CECs transfected with 100nmol/L bad siRNA or scrambled bad siRNA was analyzed by RT-PCR 48 h after transfection. Bad, but not scrambled, siRNA reduced bad mRNA levels. Bad siRNA did not alter cyclophilin mRNA levels, suggesting the specificity of this knockdown strategy. (B) Cerebrovascular endothelial cells treated with bad siRNA for 48 h before Aβ_25–35 treatment were fractionated and analyzed by Western blotting with the antibodies indicated. Bad siRNA effectively reduced mitochondrial Bad translocation (Mito.Bad), nuclear Endo G (Nuc. Endo G) and cytosolic Smac (Cyto.Smac) 24 h after Aβ_25–35 treatment. (C) Bad knockdown also reduced CEC death (determined by MTT assay and LDH assay). RT-PCR (A) and Western blots (B) are representative of three separate experiments with similar results. Data shown in panel C are expressed as mean × s.d. from three separate experiments in quadruplicate. **P < 0.05 versus control (CECs treated with Aβ_25–35 in the absence of siRNA or in the presence of a scrambled siRNA).

Discussion

We have shown that Aβ_25–35-induced CEC death was accompanied by Akt inactivation by means of dephosphorylation, occurring within 1 h after exposure to Aβ_25–35. That Akt inactivation was causally related to Aβ_25–35-induced mitochondrial dysfunction and subsequent CEC apoptosis was supported by two lines of evidence. First, Akt inhibition by wortmannin exacerbated Aβ_25–35-induced Bad activation, mitochondrial dysfunction, and CEC death. Second, enhancing Akt activity using a Tat—Akt_ca fusion protein or by viral gene transfer of a consitutively active mutant akt_ca attenuated Aβ_25–35-induced Bad activation, mitochondrial dysfunction, and CEC death. These results suggest that Aβ_25–35-induced Akt dephosphorylation activates Bad, releasing mitochondrial Endo G and Smac, and contributes to Aβ_25–35-induced CEC death. The survival-promoting activity of several growth factors, including neurotrophins, is mediated by enhancement of Akt activity (Kaplan and Miller, 2000). Conversely, there is growing evidence that a number of death-promoting stimuli cause Akt inactivation. For example, N-methyl-d-aspartate excitotoxicity is accompanied by Akt inactivation and Akt upregulation using viral gene transfer of a constitutively active akt gene prevents excitotoxic neuronal cell death (Luo et al, 2003).

Although the PI3K/Akt pathway protects cells from apoptosis caused by diverse stress stimuli, its protective role in the setting of Aβ exposure is unclear, and several reports are contradictory. For example, a recent study by Wei et al (2002) shows that Aβ_25-35 induced a weak activation of Akt together with JNK and ERK but not p38 kinase in SH-5Y cells. Martin et al (2001) have also shown that Akt activity was activated shortly after incubation with Aβ_25–35 and Aβ_1–40 with kinetics different from that of nerve growth factor in PC12 cells. However, consistent with the results of the current study, several other groups have observed down-regulation of Akt after Aβ exposure. For example, Suhara et al (2003) recently showed that virally encoded Aβ_1–42 was proapoptotic and inhibitory to Akt phosphorylation in human umbilical vein endothelial cells, which was characterized by mitochondrial dysfunction, DNA condensation, and activation of caspase-3. Kubo et al (2002) also found that Aβ_1–40 suppressed the PI-3K-dependent Akt phosphorylation but not mitogen-activated protein kinase phosphorylation in HeLa cells. These conflicting data might be due to differences in cell types and experimental conditions, and underscore the complexity of intrinsic apoptosis-regulatory genes in cell systems.

Akt phosphorylates a number of proteins which are known to regulate apoptosis (Cross et al, 1995; Datta et al, 1997; del Peso et al, 1997; Hajduch et al, 1998; Brunet et al, 1999; Kaplan and Miller, 2000); prominent among these proteins is the BH3-only protein, Bad. In this study, subsequent to Aβ_25–35-induced Akt inactivation, we observed Bad translocation from cytoplasm to mitochondria. On translocation, we found that Bad physically interacted with Bcl-x_L; Bcl-x_L, in the absence of Bad, interacts with Bax to neutralize its proapoptotic activity (Zamzami et al, 1998). That Bad activation was indeed causally related to Aβ_25–35-induced mitochondrial dysfunction including Endo G and Smac release was confirmed by the observations that specific bad knockdown with a siRNA strategy resulted in a reduction in Aβ_25–35-induced Endo G and Smac release and CEC death. Endonuclease G is an effector enzyme in the apoptotic cascade, cleaving chromatin on translocation from mitochondria to nucleus (Susin et al, 1999; Li et al, 2001). Smac, released to the cytoplasm, relieves IAP protein inhibition of caspases, resulting in the propagation of the apoptotic cascade (Du et al, 2000).

Together, these results establish an Aβ_25–35-activated death signaling cascade in CECs involving Akt inactivation and resulting in a series of cellular events. The downstream pathway involves Bad activation and translocation from the cytoplasm to mitochondria, and binding to Bcl-x_L, resulting in disruption of the mitochondrial membrane and release of cytochrome c, Smac, and Endo G. These events triggered by mitochondrial dysfunction are likely the underlying mechanism of Aβ_25–35-induced CEC apoptosis. Understanding the death signaling processes activated by Aβ will contribute to future development of strategies to prevent vascular degeneration in cerebral amyloid angiopathy.

References

Ahmed

Grimes

Bellacosa

Chan

Tsichlis

(1997) Transduction of interleukin-2 antiapoptotic and proliferative signals via Akt protein kinase. Proc Natl Acad Sci USA 94:3627–32

Behl

Davis

Lesley

Schubert

(1994) Hydrogen peroxide mediates amyloid beta protein toxicity. Cell 77:817–27

Blanc

Toborek

Mark

Hennig

Mattson

(1997) Amyloid beta-peptide induces cell monolayer albumin permeability, impairs glucose transport, and induces apoptosis in vascular endothelial cells. J Neurochem 68:1870–81

Bozyczko-Coyne

O'Kane

Dobrzanski

Murthy

Vaught

Scott

(2001) CEP-1347/KT-7515, an inhibitor of SAPK/JNK pathway activation, promotes survival and blocks multiple events associated with Abeta-induced cortical neuron apoptosis. J Neurochem 77:849–63

Brunet

Bonni

Zigmond

Lin

Juo

Anderson

Arden

Blenis

Greenberg

(1999) Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96: 857–68

Burgering

Coffer

(1995) Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature 376:599–602

Cregan

Fortin

MacLaurin

Callaghan

Cecconi

Dawson

Park

Kroemer

Slack

(2002) Apoptosis-inducing factor is involved in the regulation of caspase-independent neuronal cell death. J Cell Biol 158:507–17

Cross

Alessi

Cohen

Andjelkovich

Hemmings

(1995) Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378:785–9

Datta

Dudek

Tao

Masters

Gotoh

Greenberg

(1997) Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91:231–41

10.

del Peso

Gonzalez-Garcia

Page

Herrera

Nunez

(1997) Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 278: 687–9

11.

Dimmeler

Assmus

Hermann

Haendeler

Zeiher

(1998) Fluid shear stress stimulates phosphorylation of Akt in human endothelial cells: involvement in suppression of apoptosis. Circ Res 83:334–41

12.

Fang

Wang

(2000) Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 102:33–42

13.

Dudek

Datta

Franke

Birnbaum

Yao

Cooper

Segal

Kaplan

Greenberg

(1997) Regulation of neuronal survival by the serine—threonine protein kinase Akt. Science 275:661–5

14.

Franke

Kaplan

Cantley

Toker

(1997) Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate. Science 275:665–8

15.

Franke

Yang

Chan

Datta

Kazlauskas

Morrison

Kaplan

Tsichlis

(1995) The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell 81:727–36

16.

Fujio

Walsh

(1999) Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchorage-dependent manner. J Biol Chem 274:16349–54

17.

Green

Reed

(1998) Mitochondria and apoptosis. Science 281:1309–12

18.

Hajduch

Alessi

Hemmings

Hundal

(1998) Constitutive activation of protein kinase B alpha by membrane targeting promotes glucose and system A amino acid transport, protein synthesis, and inactivation of glycogen synthase kinase 3 in L6 muscle cells. Diabetes 47:1006–13

19.

Hase

Araki

Hayashi

(1997) Fragments of amyloid beta induce apoptosis in vascular endothelial cells. Endothelium 5:221–9

20.

Huang

Strasser

(2000) BH3-only proteins—essential initiators of apoptotic cell death. Cell 103:839–42

21.

Iadecola

Zhang

Niwa

Eckman

Turner

Fischer

Younkin

Borchelt

Hsiao

Carlson

(1999) SOD1 rescues cerebral endothelial dysfunction in mice overexpressing amyloid precursor protein. Nat Neurosci 2:157–61

22.

Imaizumi

Morihara

Mori

Katayama

Tsuda

Furuyama

Wanaka

Takeda

Tohyama

(1999) The cell death-promoting gene DP5, which interacts with the BCL2 family, is induced during neuronal apoptosis following exposure to amyloid beta protein. J Biol Chem 274:7975–81

23.

Kaltschmidt

Uherek

Wellmann

Volk

Kaltschmidt

(1999) Inhibition of NF-kappaB potentiates amyloid beta-mediated neuronal apoptosis. Proc Natl Acad Sci USA 96:9409–14

24.

Kandasamy

Srinivasula

Alnemri

Thompson

Korsmeyer

Bryant

Srivastava

(2003) Involvement of proapoptotic molecules Bax and Bak in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced mitochondrial disruption and apoptosis: differential regulation of cytochrome c and Smac/DIABLO release. Cancer Res 63:1712–21

25.

Kaplan

Miller

(2000) Neurotrophin signal transduction in the nervous system. Curr Opin Neurobiol 10:381–91

26.

Kelekar

Thompson

(1998) Bcl-2-family proteins: the role of the BH3 domain in apoptosis. Trends Cell Biol 8:324–30

27.

Kim

Kwak

Koh

(2000) Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Circ Res 86:24–9

28.

Kitamura

Onishi

Kinoshita

Shibuya

Miyajima

Nolan

(1995) Efficient screening of retroviral cDNA expression libraries. Proc Natl Acad Sci USA 92:9146–50

29.

Klippel

Kavanaugh

Pot

Williams

(1997) A specific product of phosphatidylinositol 3-kinase directly activates the protein kinase Akt through its pleckstrin homology domain. Mol Cell Biol 17:338–44

30.

Korsmeyer

(1999) BCL-2 gene family and the regulation of programmed cell death. Cancer Res 59:1693s–700s

31.

Kubo

Nishimura

Oda

(2002) Amyloid beta-peptide alters the distribution of early endosomes and inhibits phosphorylation of Akt in the presence of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). Brain Res Mol Brain Res 106:94–100

32.

Kolluri

Dawson

Cao

Hobbs

Lin

Chen

Lin

Xie

Fontana

Reed

Zhang

(2000) Cytochrome c release and apoptosis induced by mitochondrial targeting of nuclear orphan receptor TR3. Science 289:1159–64

33.

Luo

Wang

(2001) Endonuclease G is an apoptotic DNase when released from mitochondria. Nature 412:95–9

34.

Liu

Kim

Yang

Jemmerson

Wang

(1996) Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell 86:147–57

35.

Loo

Copani

Pike

Whittemore

Walencewicz

Cotman

(1993) Apoptosis is induced by beta-amyloid in cultured central nervous system neurons. Proc Natl Acad Sci USA 90:7951–5

36.

Luo

Hattori

Hossain

Hester

Huang

Lee-Kwon

Donowitz

Nagata

Snyder

(2003) Akt as a mediator of cell death. Proc Natl Acad Sci USA 100:11712–7

37.

Madesh

Antonsson

Srinivasula

Alnemri

Hajnoczky

(2002) Rapid kinetics of tBid-induced cytochrome c and Smac/DIABLO release and mitochondrial depolarization. J Biol Chem 277:5651–9

38.

Martin

Salinas

Lopez-Valdaliso

Serrano

Recuero

Cuadrado

(2001) Effect of the Alzheimer amyloid fragment Abeta(25–35) on Akt/PKB kinase and survival of PC12 cells. J Neurochem 78:1000–8

39.

Perlmutter

Myers

Barron

(1994) Vascular basement membrane components and the lesions of Alzheimer's disease: light and electron microscopic analyses. Microsc Res Tech 28:204–15

40.

Preston

Hipkiss

Himsworth

Romero

Abbott

(1998) Toxic effects of beta-amyloid(25–35) on immortalised rat brain endothelial cell: protection by carnosine, homocarnosine and beta-alanine. Neurosci Lett 242:105–8

41.

Price

Sutton

Hellermann

Thomas

(1997) beta-Amyloid induces cerebrovascular endothelial dysfunction in the rat brain. Neurol Res 19:534–8

42.

Sable

Filippa

Filloux

Hemmings

Van Obberghen

(1998) Involvement of the pleckstrin homology domain in the insulin-stimulated activation of protein kinase B. J Biol Chem 273:29600–6

43.

Schwarze

Vocero-Akbani

Dowdy

(1999) In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285:1569–72

44.

Suhara

Magrane

Rosen

Christensen

Kim

Zheng

McPhie

Walsh

Querfurth

(2003) Abeta42 generation is toxic to endothelial cells and inhibits eNOS function through an Akt/GSK-3beta signaling-dependent mechanism. Neurobiol Aging 24:437–51

45.

Suo

Fang

Crawford

Mullan

(1997) Superoxide free radical and intracellular calcium mediate A beta(1–42) induced endothelial toxicity. Brain Res 762:144–52

46.

Susin

Lorenzo

Zamzami

Marzo

Snow

Brothers

Mangion

Jacotot

Costantini

Loeffler

Larochette

Goodlett

Aebersold

Siderovski

Penninger

Kroemer

(1999) Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 397:441–6

47.

Verhagen

Ekert

Pakusch

Silke

Connolly

Reid

Moritz

Simpson

Vaux

(2000) Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 102:43–53

48.

Walker

(1997) Animal models of cerebral beta-amyloid angiopathy. Brain Res Brain Res Rev 25:70–84

49.

Wang

(2001) The expanding role of mitochondria in apoptosis. Genes Dev 15:2922–33

50.

Wei

Wang

Kusiak

(2002) Signaling events in amyloid beta-peptide-induced neuronal death and insulin-like growth factor I protection. J Biol Chem 277:17649–56

51.

Wisniewski

Wegiel

(1995) The neuropathology of Alzheimer's disease. Neuroimaging Clin N Am 5: 45–57

52.

Wisniewski

Wegiel

Vorbrodt

Mazur-Kolecka

Frackowiak

(2000) Role of perivascular cells and myocytes in vascular amyloidosis. Ann NY Acad Sci 903:6–18

53.

Chen

Ahmed

Chen

Hsu

(2001) Amyloid beta peptide-induced cerebral endothelial cell death involves mitochondrial dysfunction and caspase activation. J Cereb Blood Flow Metab 21: 702–10

54.

Moore

Hsu

Hogan

(1992) Receptor-linked hydrolysis of phosphoinositides and production of prostacyclin in cerebral endothelial cells. J Neurochem 58:1930–5

55.

Yang

Zha

Jockel

Boise

Thompson

Korsmeyer

(1995) Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell 80:285–91

56.

Yankner

(1996) Mechanisms of neuronal degeneration in Alzheimer's disease. Neuron 16:921–32

57.

Yankner

Dawes

Fisher

Villa-Komaroff

Oster-Granite

Neve

(1989) Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease. Science 245:417–20

58.

Yin

Chen

Lee

Hsu

(2002a) ATM gene regulates oxygen-glucose deprivation-induced nuclear factor-kappaB DNA-binding activity and downstream apoptotic cascade in mouse cerebrovascular endothelial cells. Stroke 33:2471–7

59.

Yin

Lee

Chen

Hsu

(2002b) Amyloid-beta induces Smac release via AP-1/Bim activation in cerebral endothelial cells. J Neurosci 22:9764–70

60.

Zamzami

Brenner

Marzo

Susin

Kroemer

(1998) Subcellular and submitochondrial mode of action of Bcl-2-like oncoproteins. Oncogene 16: 2265–82

61.

Zha

Harada

Yang

Jockel

Korsmeyer

(1996) Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 87:619–28

Aβ 25–35 Alters AKT Activity,Resulting in Bad Translocation and Mitochondrial Dysfunction in Cerebrovascular Endothelial Cells

Abstract

Keywords

Introduction

Materials and methods

Murine Cerebrovascular Endothelial Cell Primary Cultures

Treatment with Aβ and Other Chemicals

Western Blot Analysis

Immunofluorescent Staining

Generation and Purification of Tat—Akt Fusion Protein

Construction of Retrovirus-Mediated Overexpression of Akt in Cerebrovascular Endothelial Cells

RT-PCR

Co-immunoprecipitation

Bad Knockdown in Cerebrovascular Endothelial Cells with RNA Interference

Assessment of Murine Cerebrovascular Endothelial Cell Death

Results

Aβ25–35 Inactivation of Akt in Cerebrovascular Endothelial Cells

Aβ25–35 Dephosphorylation of Bad in Cerebrovascular Endothelial Cells

Endonuclease G Translocation from Mitochondria to Nucleus After Aβ25–35 Exposure

Akt Regulation of Aβ25–35-Induced Mitochondrial Dysfunction and Cell Death

Effects of bad Knockdown with siRNA on Mitochondrial Dysfunction and Cell Death

Discussion

References